The Lilly Research laboratories
Eli Lilly and Company
Indianapolis, Ind., U.S.A.
Director G. H. A. Clowes
December 9, 1922
Dr. J. J. R. MacLeod,
Department of Physiology,
University of Toronto,
My dear Dr. MacLeod:-
I enclose two copies of a letter sent by Mr. Schley to Mr. Eli Lilly yesterday re: patent situation, prior to receipt of your last telegram, to which I have just replied by wire.
You may rest assured that we shall do everything in our power to help you get a satisfactory patent as rapidly as possible.
In the light of recent developments it seems to me we should stress from the product standpoint -
(1) the elimination of the destructive trypsin by
(a) preventing its passing into the solution,
(b) preventing its acting if it does pass into the solution, this would cause acid water
(c) destroying it in the solution in case it has passes into the solution prior to so modifying the solution as to make it possible for the trypsin to act. This would cause boiling water
(2) the elimination of proteins and other undesirable toxic products.
The Toronto group are entitled to a product patent on the basis of having been the first to make a product clinically available for the cure of diabetes. The elimination of the destructive action of trypsin by one means or another and also of poisonous substances accompanying the active principle in the extract, have made this possible.